Year: 2025

Groupe BPCE is positioned well above the prudential capital requirements applicable in 2026 as laid down by the European Central Bank Paris, November 4, 2025 Groupe BPCE has received notification from the European Central Bank concerning the results of the Supervisory Review and Evaluation Process (SREP) conducted in 2025, stating the level of prudential capital requirements for 2025. The Common Equity Tier 1 (CET1) requirement applicable to Groupe BPCE on a consolidated basis is unchanged at 10.59% as of January 1st, 2026, including:• 1.69% with respect to the Pillar 2 requirement or P2R,• 2.5% with respect to the capital conservation buffer,• 1.0% with respect to the capital buffer for global systemically important banks (G-SIBs), • 0.90% with respect to the countercyclical buffers. The Total Capital requirement is also unchanged at...

PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) — via IBN — Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), a leader in AI-driven blockchain solutions focusing on data monetization, asset tokenization, and secure digital marketplaces, today announced that it has granted a worldwide exclusive license, with the right to sublicense, to Scilex Holding Company (Nasdaq: SCLX), for Datavault AI’s proprietary AI-driven technology. This license is tailored for use within the biotech and biopharma industry, enabling Scilex to create and operate a Biotech Exchange platform. By leveraging Datavault AI’s advanced data platforms, Scilex can facilitate secure tokenization, trading, and monetization of biotech assets, including genomic and DNA data, diagnostic and therapeutic products, genetic information, and drug...

Schindellegi, Switzerland – 4 November 2025 Trifork Group AGCompany announcement no. 50/2025European Regulatory News Reporting of transactions made by persons discharging managerial responsibilities Pursuant to the Market Abuse Regulation Article 19, Trifork Group AG (Swiss company registration number CHE-474.101.854) (“Trifork”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in Trifork or persons closely associated with them.1. Details of the person discharging managerial responsibilities/person closely associateda) Name Kristian Wulf-Andersen2. Reason for the notificationa) Position/status CFOb) Initial notification/Amendment Initial notification3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or...

CINCINNATI, Ohio, Nov. 04, 2025 (GLOBE NEWSWIRE) — Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the UBS 2025 Global Healthcare Conference on Tuesday, November 11, 2025, at approximately 2:00 p.m. (ET) at the PGA National Resort in Palm Beach Gardens, Florida. The presentation will be webcast live and can be accessed, along with the presentation materials, through the Chemed website at www.chemed.com (Investor Relations). The webcast replay will be available within 24 hours of the live presentation and will be accessible for 90 days. Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation’s largest provider of end-of-life hospice care...

TORONTO, Nov. 04, 2025 (GLOBE NEWSWIRE) — GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exchanges and GLBXF – OTCQX International in the US) is pleased to inform shareholders that Antimony Resources Corp. (ATMY-CSE, K8JO-FSE) have reported that they have filed a NI 43-101 Technical Report on the Bald Hill Antimony Project in New Brunswick, Canada on SEDAR Plus. Globex reported the option of the Bald Hill antimony/gold property to Antimony Resources Corp. (formerly Big Red) on January 22, 2025). The document describes the project in detail, including summaries of past work, summarizes the Phase One Drilling Program completed by Antimony Resources Corp. and indicates that the project...

Comprehensive immunogenicity data of individualized neoantigen therapeutic vaccine (INTV) TG4050, from the randomized Phase I study in operable Head and Neck Squamous Cell Carcinoma (HNSCC) patients, to be presented at SITC 2025 New TG4050 data further validate its mechanism of action and potential to reduce risk of relapse presented at ASCO 2025 First immunogenicity data in the ongoing Phase II trial in operable HNSCC expected in H2 2026Strasbourg, France, November 4, 2025, 5:50 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provides a business update on its lead asset TG4050 developed from its myvac® platform, upcoming plans, and its financial position as of September 30, 2025. TG4050 – INTV: New Data presented at SITC supports...

Aspo Plc  ANNOUNCEMENT  4.11.2025          Aspo Plc: Share repurchase 4.11.2025       In the Helsinki Stock Exchange         Trade date           4.11.2025  Bourse trade         Buy  Share                  ASPO  Amount             2 500 SharesAverage price/ share    6,5120 EURTotal cost            16 280,00 EUR          Aspo Plc now holds a total of 4 768 shares  including the shares repurchased on 4.11.2025       The share buybacks are executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5and the Commission Delegated Regulation (EU) 2016/1052.          On behalf of Aspo Plc         Nordea Bank Oyj              Sami Huttunen Ilari Isomäki       For more information, please contact:  Erkka Repo,...

Attached are the results of the shareholders’ meeting of SKEL fjárfestingafélag hf., held today, Tuesday, 4 November 2025. Further information is available from Ásgeir Helgi Reykfjörð Gylfason, CEO, at fjarfestar@skel.isAttachmentResults of the shareholders’ meeting

DASSAULT AVIATION French corporation (société anonyme) with a share capital of 62,717,627.20 euros Headquarters: 9, Rond-Point des Champs-Élysées – Marcel Dassault 75008 PARIS 712 042 456 RCS Paris Information concerning the total number of voting rights and shares as per article L. 233-8 II of the French Commercial Code (Code de commerce) and article 223-16 of the General Regulations (Règlement Général) of the French Market Authority (Autorité des Marchés Financiers)DateTotal number of sharesTotal number of voting rights10/31/2025 78,397,034Theoretical voting rights: 130,565,344 Exercisable voting rights: 130,025,255AttachmentTotal number of shares and voting rights – 31 10 25